G astroesophageal reflux disease (GERD) is among the most prevalent diseases in the United States, with approximately 10% of the population experiencing daily symptoms and up to 50% experiencing symptoms monthly. 1, 2 Antireflux surgery (ARS) is an option when symptoms are not controlled with lifestyle modification or acid-suppression therapy (AST) alone, or when complications of reflux develop (eg, esophagitis, Barrett's esophagus, stricture).
Established guidelines from the American Gastroenterological Association Institute state that ARS should be considered in patients with the following: (1) typical esophageal reflux symptoms who are responsive to, but intolerant of, proton pump inhibitor (PPI) therapy; (2) typical reflux symptoms that are considered "troublesome," especially regurgitation, despite PPI therapy; (3) typical reflux symptoms in patients who prefer a more definitive option despite symptoms being controlled adequately on PPI therapy; and (4) extraesophageal symptoms in patients in whom a reflux etiology has been established to the greatest degree possible. [3] [4] [5] ARS is estimated to improve symptoms successfully in more than 90% of patients with typical esophageal reflux symptoms (eg, heartburn, regurgitation). 6, 7 However, response is much less predictable in patients presenting with extraesophageal reflux symptoms (eg, cough, asthma/wheezing, hoarseness, throat clearing), with 1 systematic review citing ARS as being effective in 15% to 95% of affected patients. 8 Given the current uncertainties regarding the role of ARS in extraesophageal reflux, the objective of this study was to determine what patient characteristics and preoperative test parameters are associated with symptom recurrence after ARS. This study compared patients with primary extraesophageal reflux symptoms (cough, hoarseness, asthma/wheezing, throat clearing) to patients with typical GERD manifestations (heartburn, regurgitation).
Materials and Methods

Study Design
Our single-center retrospective cohort study included adult patients (age, 18 y) who underwent de novo ARS (Nissen or Toupet fundoplication) by one surgeon (M.D.H.) at Vanderbilt University Medical Center between 2004 and 2012, from an Institutional Review Board-approved de-identified clinical registry. For inclusion, patients were required to have at least 1 year of follow-up evaluation and/or be contacted by telephone. Patients were excluded if they had undergone prior foregut or fundoplication surgery.
Baseline patient characteristics recorded in the database included age, sex (male/female), and ethnicity (Caucasian, African American, Hispanic, or other). Additional covariates considered included primary and secondary presenting symptoms (typical, extraesophageal), preoperative response to AST (yes/partial/no), physiological test parameters (eg, endoscopy, pH monitoring, manometry), and surgical procedural features described later. Impedance testing parameters were not considered in the analysis because of its infrequent use in this cohort.
Endoscopy
Esophagogastroduodenoscopy procedures were performed according to the American Society for Gastrointestinal Endoscopy practice recommendations for antibiotic prophylaxis and management of antithrombotic agents. 9 Esophagitis was graded using the Los Angeles classification system, 10 and the presence of a hiatal hernia (>4 cm) was documented. In patients with noted esophagitis without a recorded LA grade or in patients with a recorded LA grade A esophagitis, endoscopic images were reviewed personally by the principal investigator (M.F.V.) to confirm the presence of erosive esophagitis.
Manometry
Manometry was performed before surgery to exclude esophageal motility disorders (eg, achalasia) and to localize the lower esophageal sphincter when pH monitoring with a 24-hour ambulatory catheter was used.
pH monitoring
Ambulatory pH monitoring was performed for 24 to 48 hours using a catheter-based device or a wireless capsule (Given Imaging, Inc, Duluth, GA). In this study, pH testing with a wireless capsule was performed in 87% (65 of 75), and a catheter-based device was used in 13% (10 of 75). All patients included in the study discontinued their AST at least 14 days before undergoing evaluation. Meals were excluded from the analysis.
Wireless capsules were calibrated by submersion in buffer solutions at pH 7.0 and pH 1.0, and then activated by magnet removal. The patients underwent esophagogastroduodenoscopy with conscious sedation for anatomic evaluation and distance measurements from the incisors to the squamocolumnar junction. Capsules then were placed using the manufacturer's delivery system at 6 cm above the squamocolumnar junction and attached with vacuum suction of 600 mm Hg. After successful placement, patients were given wireless pH recorders to wear around their waists or to keep within 3 to 5 feet at all times. Recording devices receive pH data sampling transmitted by the capsule at 433 Hz with 6-second sampling intervals. Patients were instructed to perform their normal daily activities and dietary practices. Distal esophageal pH recording was conducted over a 48-hour period. During this time, patients kept diaries of symptoms.
After completion of the study, data were downloaded from recording devices to dedicated computers using Datalink software from Medtronic (Minneapolis, MN). Patient diary information was entered into the computer-based record manually. Measurement of the total, upright, and supine percentages of time when esophageal pH was less than 4 was determined for day 1 and day 2 (if applicable) of the study. Acid exposure time (% total time pH < 4) greater than 5.5% per day was considered abnormal. 11, 12 It is important to note that the primary analysis approach when using total time the pH was less than 4 as a predictor was to treat this covariate as a continuous rather than a binary variable. The continuous-variable approach was more powerful and removed the need for choosing a normative cut-off value.
Antireflux Surgery
Patients with evidence of GERD on pH monitoring and/or endoscopy (ie, presence of esophagitis) were counseled about treatment options including continued medical management or fundoplication. Medical management involved continued twice-daily PPI with or without an H2-receptor antagonist. All patients opting for surgery were evaluated and had surgical fundoplication performed by the same surgeon (M.D.H.). All patients underwent laparoscopic fundoplication. No patients required conversion to an open procedure.
Surgical technique used the standard 5-port laparoscopic abdominal set-up. The procedure consisted of abdominal insufflation with carbon dioxide gas, retraction of the left lobe of the liver, dissection and identification of the right and left diaphragmatic crura, and takedown of the short gastric vessels using a harmonic scalpel. After the diaphragmatic crura were reapproximated using 2 to 3 interrupted nonabsorbable sutures, the posterior fundus of the stomach was passed through the retroesophageal window to create the fundoplication. A 60F bougie was used in all cases to assist in calibration of the fundoplication. All patients then received routine postoperative care.
Primary Outcome
The primary end point was the time to recurrence of the primary presenting symptom. This was defined by patient report of partial or total recurrence of the primary presenting symptom at follow-up visits recorded in the patient's chart or by telephone contact. Partial recurrence was defined as postoperative recurrence or persistence of the primary symptom, but with improvement from preoperative severity. Total symptom recurrence was defined as postoperative recurrence or persistence without improvement from preoperative severity. The same return-of-symptom questions were asked by the operating surgeon or gastroenterologist at all postoperative visits or by the study investigators if a follow-up telephone call was warranted. Demographic and physiologic variables were also measured along with correlation of symptom recurrence and restart of AST.
Study Oversight and Data Collection
Research for this study was performed through the Digestive Disease Research Center at Vanderbilt University Medical Center.
Study data were collected by 1 investigator (J.T.K.), and then rechecked and validated by a second reviewer (R.D.N.). Data were managed using Research Electronic Data Capture (REDCap, Nashville, TN) electronic data capture tools hosted at Vanderbilt University. 13 REDCap is a secure, web-based application designed to support data capture for research studies.
Statistical Analysis
Continuous variables were summarized using the median and interquartile range, whereas categoric variables were summarized using percentages. Time-torecurrence analyses used the surgical date as time zero. The Kaplan-Meier method was used to compare the time to recurrence between typical and extraesophageal reflux groups and by preoperative responsiveness to AST. Differences were assessed using log-rank tests. Cox proportional hazards regression was used to estimate the adjusted association between baseline covariates and time to symptom recurrence. Results from Cox models were presented as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). Investigators selected covariates hypothesized to influence ARS effectiveness for inclusion in the regression. These included primary symptom (typical vs extraesophageal), preoperative response to AST (yes/partial/no), presence of esophagitis (yes/no), and age. All analyses were conducted using the R language for statistical computing following principles for reproducible analyses in research. 14 Table 1 .
Results
Patients and Study Interventions
All patients had either abnormal pH monitoring (defined by total time pH < 4 that was >5.5% in a 24-hour period) or endoscopic evidence of erosive esophagitis. Approximately 57% of patients in both symptom groups (ie, typical and extraesophageal) had reflux parameters in the moderate-to-severe category as defined by the total time pH < 4 more than 10% in a 24-hour period.
Univariate Analyses
The median time to recurrence of symptoms in the overall cohort was 68 months (95% CI, 44 to >132 mo). The median time to symptom recurrence in the extraesophageal cohort was 11.5 months (95% CI, 5-59 mo) compared to more than 132 months (95% CI, 69 to >132 mo) in the typical cohort. Symptom recurrence after ARS was more common in the extraesophageal group and among preoperative AST nonresponders (Figures 2 and 3) (P < .01). Fundoplication was most successful at the 1-year follow-up evaluation among patients with primary typical reflux symptoms who had a full or partial preoperative response to AST (typical and AST responsive, 91.5% in remission vs extraesophageal and AST nonresponsive, 33.3%; P < .01). Extraesophageal patients who had a full or partial preoperative response to AST were more likely to have symptom resolution with fundoplication than AST nonresponders with extraesophageal symptoms (AST responsive, 58.3% in remission vs AST nonresponsive, 33%; P < .01) (Figure 4) . Similarly, patients with typical GERD symptoms who were AST responders were more likely to have symptom resolution with fundoplication compared to AST nonresponders with typical symptoms (AST responsive, 91% in remission vs AST nonresponsive, 78.9%; P < .01) (Figure 4) . No other variables were associated with symptom response (Table 2) . It is important to note that a hiatal hernia size greater than 4 cm and total time pH less than 4 greater than 12% were associated with a more favorable outcome at 12 months on a Kaplan-Meier survival analysis. However, past 12 months, the survival curves for these covariates converged.
Also of note, in the primary extraesophageal symptom cohort, patients with co-existing typical symptoms did not have a lower rate of symptom recurrence. However, of the 31 patients with co-existing extraesophageal and typical reflux symptoms, extraesophageal symptoms recurred earlier than the typical symptoms (P < .01).
Multivariate Analysis
The presence of extraesophageal reflux symptoms as the primary chief complaint was associated with symptom recurrence compared to patients with primary typical reflux symptoms after adjusting for preoperative response to AST, presence of esophagitis, and age (HR, 2.34; 95% CI, 1.31-4.17) ( Table 2 ). Nonresponse to AST preoperatively was also significantly associated with postoperative symptom recurrence in the adjusted analysis (HR, 3.85; 95% CI, 2.05-7.22) ( Table 2) .
Discussion
This investigation found that patients with primary extraesophageal reflux symptoms and lack of preoperative response to acid-suppression therapy had a greater risk of symptom recurrence after antireflux surgery. These 2 factors were synergistic as together they conferred the highest risk of symptom recurrence whereas the presence of only 1 factor was associated with an intermediate risk of recurrence. Subjects with primary typical reflux symptoms and a full or partial preoperative response to AST had a greater than 90% chance of maintaining symptom resolution at 1 year. These findings are consistent with and expand on prior observations. [15] [16] [17] [18] [19] [20] Of note, patients with primary extraesophageal reflux symptoms who had co-existing typical GERD symptoms were not less likely to experience symptom recurrence. This finding contrasts with that from a prior study by Francis et al 21 and may relate to inadequate power, because only 36 patients with extraesophageal reflux symptoms were analyzed herein.
Interestingly, although all patients had either abnormal pH monitoring or endoscopic evidence of esophagitis, the severity of acid reflux on these tests was not associated with time to symptom recurrence. This finding, although initially surprising, is consistent with a prior report by Morgenthal et al 17 in which 24-hour pH monitoring and the presence of Barrett's esophagus had poor predictive value for symptom response after ARS. One hypothesis for this finding is that clinically significant reflux on endoscopy or on physiologic testing, regardless of severity, is sufficient enough to determine appropriate candidacy for surgery.
It is important to note that the severity of acid reflux on pH monitoring and larger hiatal hernia size were associated with a more favorable outcome at 12 months. This is consistent with a prior report by Francis et al. 21 However, this effect trended to become insignificant past 1 year.
Recent studies have cast doubt on the diagnostic utility of symptom index and symptom association probability in GERD. [22] [23] [24] In nearly 50% of patients with pathologic esophageal acid exposure, a positive association between symptom occurrence and actual reflux episodes on pH testing was not present. 25 One recent study by Broeders et al 26 found symptom association probability to have no prognostic value in determining outcome after ARS. This is consistent with our study, which showed no association with symptom indices and symptom response.
Our study is unique in that it fills a gap in our current understanding of physiologic testing and response to therapy. Currently, very few studies have been conducted on a large scale (>100 patients) that have comprehensively investigated the preoperative work-up involved for a patient being considered for ARS. This includes preoperative response to AST, physiologic testing including pH monitoring and manometry, symptom indices, and endoscopic findings to determine which can significantly predict symptom response to ARS in both typical and extraesophageal reflux groups. In addition, very few studies have followed up patients after fundoplication to the extent of time as was performed in this study. Moreover, the patients included in our study underwent surgery by a single surgeon at a single center. This reduced variability in surgical technique and thus minimized the possibility of confounding outcome. The results from our study provide prognostic value that can help guide appropriate patient selection for ARS in the future.
Proton pump inhibitors are highly effective at reducing gastric acid production. Failure of response to this treatment suggests that symptoms are not caused by acid reflux and thus are less likely to respond to fundoplication. Alternative causes for the patient's symptoms must be explored in these cases. It is important to emphasize that our findings do not imply that ARS should not be considered as a therapeutic option for patients with extraesophageal reflux symptoms. However, in the setting of AST nonresponsiveness and unimpressive physiologic testing, one might reconsider whether reflux is the etiology of the patient's symptoms.
The limitations of this study include its retrospective design, single-center cohort, and rather homogenous patient population (predominantly Caucasian and obese). The design consequently led to many patients missing information that could increase the risk of type II statistical error. In addition, the majority of the study population was obese (BMI 30), which has been shown in past literature to be a negative predictor of response. 17 Our data did not find obesity to be an independent risk factor, possibly owing to the small number of patients with a low BMI.
Another weakness of this study was the rather large number (n ¼ 81) of patients excluded for lack of sufficient follow-up. This could have included patients doing well without symptom recurrence (and thus no need to re-present) or patients with symptom recurrence seeking medical care closer to their home.
An additional limitation of this study included the lack of preoperative and postoperative standardized questionnaires to assess symptom severity before and after fundoplication. Although all preoperative and postoperative visits were conducted by the same personnel who reliably asked the same questions regarding symptom response, it would have been beneficial to use a validated standardized questionnaire assessing symptom severity on a linear scale. This can be the goal for a prospective study on this subject in the future.
In conclusion, the most reliable factors associated with symptom recurrence after antireflux surgery are the presence of extraesophageal reflux symptoms as the primary chief complaint and a lack of preoperative response to acid-suppression therapy. The severity of reflux on physiologic testing or endoscopy was found to be associated poorly with symptom response. In the future, a multicenter prospective trial will need to be conducted in a diverse study population using a standardized assessment tool to confidently determine the utility of the variables discussed in this study.
